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ABSTRACT
Kidney transplant (KT) recipients are at greater risk of developing some 
cancers than the general population. Moreover, cancer is the only cause of death 
that is currently increasing after kidney transplantation. We analyzed incidence, risk 
factors and characteristics of post-transplant malignancies (solid organ tumors and 
lymphoproliferative disorders) at our center in 925 KT recipients (1979-2014). Sex 
differences were particularly assessed.
One hundred and eight patients (11.7%) developed solid organ tumors (76.9%) 
or lymphoma (23.1%). Twenty-one percent of patients who reached 20 years after 
KT developed cancer, with a median post-KT time to diagnosis of 7.4 years. Most 
common solid organs affected were lung (30.1%), prostate (10.8%), bladder (9.6%), 
and native kidney (7.2%). When analyzing standardized incidence ratios (SIR) by 
gender compared to the general population, relative risk was increased in women 
(SIR = 1.81; 95%CI, 1.28–2.45) but not significantly increased in men (SIR = 1.22; 
0.95–2.52). Regarding specific types, gynecological (SIR = 11.6; 4.2–22.7) and lung 
(SIR = 10.0; 4.3–18.2) in women, and bladder (SIR = 16.3; 5.9–32.1) in men were 
the most affected locations. Thymoglobulin, a polyclonal antibody that has been used 
as an immunosuppressive agent in kidney transplantation over the last decades, 
was a significant risk factor for developing cancer in adjusted regression analysis 
[IRR = 1.62, 1.02–2.57; p = 0.041], and was associated with lower patient survival.
Compared with the general population, the incidence of post-KT non-skin cancer 
is almost two-fold higher in women but not significantly higher in men. Lung is the 
most common solid organ affected. Thymoglobulin induction therapy is associated 
with a greater risk.
INTRODUCTION
In patients with end-stage kidney disease (ESKD) 
and requirement of renal replacement therapy, kidney 
transplantation (KT) is preferred over dialysis as it 
provides both improved patient survival and quality of 
life at lower costs [1–3]. However, an increased incidence 
of cancer has been reported in this population [4, 5]. 
Moreover, the outcomes and prognosis of KT patients with 
some cancers are substantially worse than in those patients 
with cancer but without kidney disease [6–8].
The cumulative incidence of de novo cancer after 
transplantation is 9–10% at 10 years and between 10–27% 
at 20 years, excluding non-melanoma skin cancer [3, 9–11]. 
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The importance of cancer in KT relies on its impact on 
patient survival, being the second long-term cause of death in 
KT patients [12]. In fact, cancer after KT is the only cause of 
death that is currently increasing [13]. Immunosuppression 
causes a substantial increase in cancer risk [14, 15].
Age and male sex are recognized risk factors 
associated with the development of malignancy after KT 
[4]. Other factors have been described: underlying kidney 
disease, type of donor (deceased and expanded donor are 
at substantially increased risk of cancer compared with 
living donor) [16], cancer before transplant [17, 18], 
oncogenic viruses such as human papillomavirus (HPV) 
or Epstein-Barr virus (EBV) [19], acute rejection (AR) 
[20], race [21] or tobacco [22]. However, the literature 
on this subject is heterogeneous and except for cancers 
associated with lifestyle factors like tobacco or caused by 
viral infections, most of these risk factors have not been 
related to a specific cancer location.
In addition, overall immunosuppressive dose is 
associated with an increased risk of cancer following 
transplantation. Immunosuppression may facilitate 
carcinogenesis by decreasing mechanisms involved in 
the immunologic control of oncogenic viral infection 
and cancer immunosurveillance or by direct DNA 
damage [12]. Currently available immunosuppressive 
therapies influence different anti-cancer pathways, 
but the contributive effect of each agent is not well 
established at this moment [23]. T cell-depleting agents, 
such as thymoglobulin, are widely used as induction 
immunosuppressive therapy and to treat rejection in KT 
recipients. Earlier studies have demonstrated that the 
use of T cell-depleting antibodies is associated with an 
increased risk for post-transplantation lymphoproliferative 
disorders (PTLD) compared to interleukin-2 receptor alpha 
chain (IL-2Ra) agents or no induction therapy [24, 25]. On 
the other hand, mammalian target of rapamycin inhibitors 
(mTORi) have been reported to inhibit cancer progression 
in animals and to be associated with reduced incidence 
of posttransplant de novo malignancies in humans [26]. 
Nonetheless, authors have not been able to demonstrate 
improved survival in KT recipients taking mTORi [27].
The increased risk of post-KT malignancy is not 
spread evenly over all types of cancer [24]. Certain 
malignancies, such as lung, liver and kidney cancer, 
melanoma and non-melanoma skin cancer, PTLD, 
and thyroid cancer, are increased. Furthermore, risk is 
particularly high for malignancies caused by viral infections, 
including anogenital cancers (human papillomavirus), non-
Hodgkin lymphoma and Hodgkin lymphoma (both due to 
EBV), Kaposi sarcoma (human herpes virus 8) and liver 
cancer (hepatitis C and B viruses) [4, 9, 14, 23].
Several population-registries have analyzed the 
incidence of cancer after KT in the United States [4], 
Australia and New Zealand [10], Europe [28] and Asia 
[29, 30]. Nevertheless, there is little evidence in the 
literature about incidence, risk factors and cancer location 
in southern European transplanted patients (mostly 
reported in Italian population) [31]. No data is available in 
Spainish renal transplant population, the country with the 
highest rate of KT per million population.
The aim of our study was to analyze the incidence of 
cancer in our cohort of KT recipients and compare it with 
general population, as well as to study the characteristics 
and risk factors of post-transplant malignancies (PTM). 
Donor characteristics, recipient’s medical history 
and immunosuppression regimens were evaluated. In 
particular, a gender effect was assessed.
RESULTS
Prevalence of cancer and distribution
During the observation period (May 1979 to April 
2016), from a total of 925 KT recipients, 108 (11.7%) 
developed at least one cancer. Eighty-three patients 
(76.8%) had at least one solid organ tumor, and 25 
patients (23.1%) had a lymphoproliferative disorder. 
One patient had both entities (solid organ tumor and a 
lymphoproliferative disorder). (Figure 1).
Lung cancer was the most frequently observed, 
accounting for 30.1% of all solid organ cancers in our 
cohort, followed by prostate (10.8%), urinary bladder 
(9.6%), native kidney (7.2%) and gynecological tumors 
(7.2%). The distribution of solid organ cancers is shown 
in Figure 2.
Median post-KT time to cancer diagnosis was 7.4 
years (IQR 3.2-9.7), with an overall cumulative incidence 
of PTM at 20 years after transplantation of 20.7%. 
(Figure 3).
Estimation of cancer risk in KT compared to the 
risk in the general population
Based on these data, we determined that the 
estimated incidence rate of PTM in our cohort was 1536 
cases per 100,000 inhabitants/year. This was higher than 
in general population in Catalonia, where the estimated 
incidence rate for malignancies (excluding non-melanoma 
skin cancer) is 393.4 cases per 100,000 inhabitants/year 
for women and 557.6 cases per 100,000 inhabitants/year 
for men [32] (Figure 4). Relative risks of non-skin cancers 
compared to the general population in Catalonia were 
expressed as age standardized incidence ratios (SIRs). 
When analyzing SIRs computed using sex of overall PTM 
compared to the general population in Catalonia, relative 
risk was increased in women (SIR = 1.81; 95% CI, 1.28–
2.45) but not significantly increased in men (SIR = 1.22; 
95% CI, 0.95–2.52). Nevertheless, in both sexes a wide 
range of malignancy types had more pronounced risk 
comparing with the general population. The locations 
with greatest risk were: gynecological (SIR = 11.59; 
95% CI, 4.17–22.71), lung cancers (SIR = 10.05; 95% 
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CI, 4.29–18.22) and PTLD (SIR = 5.95; 95% CI, 2.54–
10.79) in women, and bladder (SIR = 16.35; 95% CI, 
5.88–32.05), PTLD (SIR = 5.54; 95% CI, 3.22–8.49) and 
native kidney cancers (SIR = 4.48; 95% CI, 1.78–8.41) in 
men. On the contrary, the relative risk of malignancy types 
occurring most frequently in general population was only 
moderately elevated or not elevated, e.g., breast, prostate 
and colorectal. (Table 1).
Basal characteristics and risk factors
Baseline characteristics of recipients, donors, 
and KT are shown in Table 2. Mean recipient age at 
time of transplantation was 47.9 years (SD 14.2 years). 
The majority of recipients were male (62.8%) and 
Caucasian (93.3%). The most frequent primary renal 
disease was glomerulonephritis (n = 217, 24.4%), 
followed by polycystic kidney disease (n = 120, 13.5%). 
87.7% of recipients were on hemodialysis before KT 
and, on average, they spent 22 months (IQR 11–41) on 
dialysis prior to KT. Kidney donors were predominantly 
male (57.9%), Caucasian (95.2%), and with a mean age 
of 46.9 (± 16.3) years-old. Induction immunosuppressive 
treatment was based on anti-CD25 drugs in 49.9% of 
cases, and only 22.8% of recipients received T-cell 
depleting agents. The most common maintenance 
Figure 1: Patients flow-chart. Abbreviations: KT: Kidney transplant, SOC: Solid organ cancer, PTLD: Post-transplantation 
lymphoproliferative disorders.
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Figure 2: Post-transplant solid organ cancer distribution. Graph shows the spectrum of malignancies after kidney transplantation 
(number of cases).
Figure 3: Cumulative incidence of post-transplant malignancies. Cumulative incidence of post-transplant malignancies after 
kidney transplantation, according to time since transplant.
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immunosuppressive regimen consisted of prednisone, 
calcineurin inhibitors and mycophenolic acid.
No differences were found among recipients with 
and without cancer in terms of age at transplantation, sex, 
cause of ESKD, pre-transplant malignancy, previous KT, 
type of renal replacement therapy (RRT), time on RRT, 
donor characteristics between groups, biopsy proven 
AR, CMV infection and BK virus. Likewise, initial and 
one-year treatment after transplantation with calcineurin 
inhibitors or mTORi showed no association with PTM 
development.
In the univariate analysis, recipient´s Caucasian race 
(92.5% vs 99.1%, p = 0.011), thymoglobulin induction (34% 
vs 21.3%, p = 0.005), maintenance immunosuppression 
with cyclosporine vs tacrolimus (55.3% vs 38.3%, 
p = 0.002) and treatment with mycophenolate mofetil 
(MMF) 1 year after-KT (60.8% vs 50%, p = 0.036) were 
significantly associated with the development of cancer 
after transplantation. (Table 2).
However, Poisson Regression analysis confirmed 
that only thymoglobulin induction was an independent risk 
factor for post-KT cancer diagnosis [Incidence Rate Ratio 
(IRR) 1.62 (95%CI, 1.02–2.57), p = 0.041). The association 
between cancer and maintenance immunosuppression 
with cyclosporine vs Tacrolimus or MMF was lost after 
adjustment for covariates (recipient age, type of donor and 
thymoglobulin induction). (Table 3).
On the other hand, the number of patients treated 
with thymoglobulin was similar between those who 
developed PTLD and solid organ cancer (36.4% vs 33.8% 
respectively, p = 0.823).
Survival analysis
Kaplan Meier analysis showed that patients with 
PTM had lower survival rates compared to patients who 
did not develop cancer at the end of follow-up. Ten-year 
patient survival was 89.8% in those recipients without 
cancer vs 10.7% in those patients who developed cancer 
(p<0.001). (Figure 5A). Death-censored graft survival 
analysis (grafts lost not due to patient death) did not show 
statistically significant differences between patients with 
PTM and those who did not develop cancer at 10 years of 
follow up (62.1% vs 68.3, p<0.001). (Figure 5B).
Figure 4: Estimated incidence of post-transplant malignancies (PTM) compared to general population in Catalonia. 
Comparison of estimated incidence rates of PTM between our cohort (1536 cases per 100,000 inhabitants/year) and the general population 
in Catalonia (393.4 cases per 100,000 inhabitants/year for women and 557.6 cases per 100,000 inhabitants/year for men). Abbreviations: KT: 
Kidney transplant, M: Men, W: Women.
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DISCUSSION
This retrospective study analyzed the incidence and 
risk factors of cancer in a cohort of 925 KT recipients. 
The main finding is that the true increase in cancer in KT 
compared with the general population occurs mostly in 
women. We observed an incidence of 11.7% PTM, with 
an overall cumulative incidence that reached 20.7% of 
patients at 20 years. Lung was the most common solid 
organ affected. Compared with the general population, the 
greatest increase was seen in gynecological malignancies, 
lung cancer and PTLD in women; and bladder, PTLD and 
kidney cancer in men. Cancer conferred lower patient 
survival and only thymoglobulin was an independent risk 
factor for PTM diagnosis.
The increased incidence of cancer in KT recipients 
is well established [4, 11, 14, 28-31, 33]. Previous series 
and reports have described that cumulative incidence 
of solid organ cancers after KT increases from 4–5% at 
5 years to 10% at 10 years and to >25% after 20 years 
of KT, similar to our results [9-11, 34]. As expected, 
the incidence of cancer after KT in our cohort was also 
increased compared to general population with a SIR of 
1.81 in women and a non-significant 1.22 in men. These 
rates were lower than the ones described in previous 
studies with an incidence of cancer among KT recipients 
two to four-fold higher than those age and sex-matched 
individuals from general population [4, 14, 28–30, 35]. 
Despite that apparent difference with the previously 
published data, our results are quite similar to those found 
in the European population [28, 31].
As we previously mentioned, cancer locations in 
KT patients differ from malignancy types occurring most 
frequently in general population (e.g., breast, prostate 
and colorectal). The most affected cancer locations in 
Catalonia [32] and Hospital del Mar [36] are prostate, 
colorectal, breast and lung. When analyzing organ 
location affected in our cohort, PTLD, lung, prostate 
and bladder were the most frequent PTM, although the 
greatest increase in PTM incidence among KT recipients 
compared with the general population was seen in 
gynecological malignancies, lung cancer and PTLD in 
women; and bladder, PTLD and kidney cancer in men. 
Interestingly, this cancer distribution was slightly different 
Table 1: Standardized incidence ratios by specific cancer types and gender
 Women  Men  
Organ Location Number of cases at 
sample
SIR (95% CI) Number of cases at 
sample
SIR (95% CI)
Lung 8 10.05 (4.29 - 18.22) 17 2.22 (1.29 - 3.4)
Bladder 2 5.76 (0.54 - 16.51) 6 16.35 (5.88 - 32.05)
PTLD 8 5.95 (2.54 - 10.79) 17 5.54 (3.22 - 8.49)
Gynecological 6 11.59 (4.17 - 22.71) - -
Kidney 2 4.98 (0.47 - 14.29) 7 4.48 (1.78 - 8.41)
Oral Cavity 2 8.24 (0.78 - 23.61) 3 1.6 (0.3 - 3.91)
Stomach 0 - 4 2.78 (0.72 - 6.18)
Colorectal 2 0.72 (0.07 - 2.05) 3 0.4 (0.08 - 0.98)
Liver 1 3.62 (0 - 14.19) 2 1.33 (0.13 - 3.82)
Pancreas 1 1.92 (0 - 7.52) 1 0.83 (0 - 3.25)
Breast 4 0.85 (0.22 - 1.88) 0 -
Prostate - - 9 0.77 (0.35 - 1.35)
Brain 0 - 1 1.48 (0 - 5.8)
Thyroid 1 2.86 (0 - 11.2) 0 -
Eye 0 - 1 0.06 (0 - 0.25)
     
All cancers 37 1.81 (1.28 - 2.45) 71 1.22 (0.95 - 1.52)
Standardized incidence ratios (SIRs) and 95% confidence intervals for most common de novo malignancies according to 
sex compared to the general population in Catalonia. Abbreviations: PTLD: Post-transplant lymphoproliferative disorder.
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Table 2: Univariate analysis comparing KT recipients with and without solid organ cancer or lymphoma
 ALL WITHOUT cancer WITH cancer p- Value
 (n=925) (n=817) (n=108)  
Basal characteristics     
Recipient age (years, mean ± 
SD) 47.9 ± 14.2 47.8 ±14.4 48.32 ± 13 0.765
Sex Female (n, %) 345 (37.2) 308 (37.6) 37 (34.3) 0.499
Caucasian race (n, %) 857 (93.3) 751 (92.5) 106 (99.1) 0.011
Arterial hypertension (n, %) 744 (81%) 663 (81.8%) 81 (75%) 0.194
Diabetes mellitus (n, %) 115 (12.5%) 106 (13%) 9 (8.3%) 0.166
Primary kidney disease: PKD 
vs. others (n, %) 120 (13.5) 99 (12.7) 21 (29.4) 0.054
Pre-KT cancer (n, %) 42 (4.5) 36 (4.4) 6 (5.6) 0.590
Previous transplant (n, %) 131 (14.2) 117 (14.3) 14 (13) 0.704
RRT before KT (n, %)    0.088
 None 19 (2.1) 19 (2.4) 0 (0)  
 HD 131 (14.2) 694 (86.9) 101 (94.4)  
 PD 87 (9.6) 82 (10.3) 5 (4.7)  
 KT 5 (0.6) 4 (0.5) 1 (0.9)  
Time in RRT (months, median 
[IQR]) 22 [11–41] 22 [11–40] 23 [11–41] 0.925
Type of donor (n, %)    0.059
 Standard criteria donor 550 (60.4) 476 (59.2) 74 (69.8)  
 Expanded criteria donor 258 (28.4) 232 (28.9) 26 (24.5)  
 Living donor 102 (11.2) 96 (11.9) 6 (5.7)  
Donor age (years, mean ± SD) 46.9 ± 16.3 47.3 ±16.3 43.9 ± 16.2 0.034
Donor sex female (n, %) 371 (42.1) 331 (42.5) 40 (38.8) 0.474
Donor Caucasian race (n, %) 793 (95.2) 703 (95.1) 90 (95.7) 0.792
Initial immunosuppression     
Thymoglobulin induction (n, %) 185 (22.8) 152 (21.3) 33 (34) 0.005
Calcineurin inhibitor (n, %) 788 (94.5) 695 (94.6) 93 (93.9) 0.800
Mycophenolate (n, %) 589 (64.2) 529 (65.2) 60 (56.1) 0.063
mTOR inhibitor (n, %) 21 (2.3) 20 (2.5) 1 (0.9) 0.319
1 year afterKT 
immunosuppression     
Calcineurin inhibitor (n, %) 778 (91.8) 682 (91.7) 96 (92.3) 0.824
Tacrolimus levels (ng/ml, mean 
± SD) 8.2 ± 3 8.1 ± 3 9 ± 3.1 0.156
Cyclosporine levels (ng/ml, 
median [IQR]) 212 [176–322] 214 [177–344] 208.5 [175–252] 0.678
Tacrolimus use (n, %) 470 (60.4) 422 (61.9) 48 (50) 0.026
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in comparison with other PTM series and publications in 
which lip, thyroid and liver had relatively higher 
incidences [4, 35, 37–41]. Although 68% of lung cancers 
were in male recipients, when analyzing SIRs computed 
in our cohort compared to the general population in 
Catalonia, relative risk was more increased in women 
(SIR = 10.05 vs 2.22 in men). This could be explained by 
the large difference in lung cancer rates among men and 
women in the Catalan population, where men presented 
with significant higher rates than women (82.8 vs 17.6 
per 100,000 inhabitants-year, respectively) compared to 
other registries where lung cancer incidence was not that 
different between sexes [42]. In our cohort, eight women 
had lung cancer: 6 of them were former or active smokers 
and one was diagnosed early post-transplant (probably 
not related to immunosuppression). Previous authors have 
also described a more significant increased risk of lung 
cancer in female transplant recipients compared to male 
recipients [43].
Observational studies and registries analyses 
have shown a great variety of PTM risk factors. Age 
at transplantation confers an increased absolute risk. 
However, whereas the absolute risk of cancer among KT 
recipients increases with older age, the higher relative 
risk of cancer seems to be greatest in younger transplant 
recipients, which is in part owing to the scarcity of cancer 
in the general population at younger ages [34, 40, 44]. 
Similarly, it has been described up to 20-30% higher 
risk of cancer for male and white ethnicity transplant 
recipients [4, 5, 21]. However, several studies comparing 
sex differences in PTM rates do not confirm this data [11, 
43–45]. A recent multicenter study of 262 female kidney 
graft recipients in Vienna reported that 12.2% developed 
PTM within the first 8.4 years after KT, similar incidence 
to the one reported in the majority of the studies that 
usually include men [46]. In agreement with our findings, 
two studies have described a higher risk of cancer between 
female KT recipients than men. Kim et al.[43] reported 
Table 3: Multivariate analysis: poisson regression
 IRR 95% confidence interval p- Value
Recipient age 1.014 [0.997 - 1.032] 0.112
Type of donor (living donor 
vs others) 0.360 [0.086 - 1.503] 0.086
Thymoglobulin induction 1.619 [1.019 - 2.571] 0.041
Tacrolimus vs. Cyclosporine 
1 year after KT 0.731 [0.409 - 1.307] 0.291
Mycophenolate 1 year after 
KT 0.745 [0.427 - 1.298] 0.298
Abbreviations: IRR: Incidence rate ratio, KT: Kidney transplant.
 ALL WITHOUT cancer WITH cancer p- Value
 (n=925) (n=817) (n=108)  
Basal characteristics     
Mycophenolic acid derivatives 
use (n, %) 503 (59.5) 451 (60.8) 52 (50) 0.036
mTOR inhibitor use (n, %) 54 (6.4) 51 (6.9) 3 (2.9) 0.120
Follow-up     
Biopsy proven acute rejection 
(n, %) 130 (14) 117 (14.3) 13 (12) 0.527
CMV infection (n, %) 125 (13.8) 108 (13.5) 17 (16) 0.477
BK virus (n, %) 25 (3.3) 23 (3.4) 2 (2.4) 0.616
Abbreviations: SD: Standard deviation, PKD: Polycystic kidney disease, KT: Kidney transplantation, RRT: Renal 
replacement therapy, HD: Hemodialysis, PD: Peritoneal dialysis, IQR: Interquartile range, mTOR: Mammalian target of 
rapamycin inhibitor, CMV: Citomegalovirus.
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Figure 5: Patient (A) and Graft (B) survival in patients with and without solid organ cancer or lymphoma. (A) Kaplan–
Meier curve shows twenty-year death-censored graft survival of kidney transplantation patients with and without cancer. (B) Kaplan–Meier 
curve shows twenty-year mortality rates of kidney transplantation patients with and without cancer.
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a higher age-standardized SIR for all cancers in female 
recipients (SIR = 1.9 vs 1.6 in men). Webster et al.[44] 
found a strong likelihood that women would be diagnosed 
with a cancer if got a KT before the age of 45 compared 
to men (males vs. females <45 years HR 0.76). Probably, 
the role of virus-related gynecological neoplasms might 
influence this increased risk in women. It is far known that 
KT recipients have a high risk to develop virus-associated 
cancers such as HPV related anogenital ones. Female 
recipients have 14-fold increased risk of cervical cancer, 
up to 50-fold of vulvar cancer and up to 100-fold of anal 
cancer [47–50]. Epidemiological studies often suffer 
from underreporting of events, which typically leads to 
an underestimation. However, in our cohort women had 
been followed-up very closely and including regular 
gynecologic visits in addition to the routine follow-up 
visits due to KT. Catalan female KT recipients have up 
to 11 times more risk of having a gynecological cancer 
than general population women counterparts. This risk, 
together with 10-fold increase in lung cancer probably 
explain the higher global SIR in women female patients 
compared to men that we found in our cohort.
Other key risk factors for the development of cancer 
after-KT would be time on dialysis before transplantation, 
donor characteristics, having a previous KT or pre-
transplant cancer history, immunosuppression treatment, 
biopsy proven AR and other immunological factors, 
smoking or alcohol use and oncogenic viruses [5, 16, 
17, 19, 20, 22, 44, 51]. On the contrary, KT recipients 
with diabetes mellitus seem to have a 20–30% lower 
risk of cancer in the USA, Australia and New Zealand 
[5, 44]. Polycystic kidney disease (PKD) has also been 
related to a lower incidence of cancer compared to 
other causes of ESKD in KT patients [52]. We found 
no differences between groups in terms of recipient and 
donor characteristics, having or not pre-transplant cancer, 
previous KT or AR. Unfortunately, some data such as 
lifestyle (tobacco, alcohol use, etc) and oncogenic viruses 
like HPV and EBV were not available in our study.
The increased incidence of cancer in KT recipients 
is largely attributed to immunosuppression. Prior studies 
have focused on the relationship between PTM and 
different immunosuppressive agents, dose regimens 
and duration of the immunosuppressive therapy [3, 25, 
53, 54]. The effect of each drug on cancer risk remains 
controversial and the increased risk of cancer may be 
mediated by the total burden of immunosuppression more 
than by the agent itself [3, 55]. However, information 
on dose and duration of therapy is not complete in most 
databases so researchers tend to investigate the relationship 
between PTM and selected immunosuppressive agents 
used for induction/maintenance therapy. Some studies have 
shown an association of induction immunosuppression 
with T cell-depleting antibodies with an increased risk 
of PTLD and melanoma [23, 25, 56]. In contrast, IL-2Ra 
induction has not been associated with significant increase 
of PTM [23]. In our study thymoglobulin induction was an 
independent risk factor for cancer. In fact, it was related 
to a 62% increased risk of having a new cancer diagnoses 
compared with those patients who did not received the 
drug, although it was not relate to any specific cancer 
location.
In terms of maintenance immunosuppression, 
Gallagher et al.[3] found no differences when analyzing 
overall cumulative incidence of non-skin cancer 20 
years after transplantation between three different 
immunosuppression strategies: azathioprine and 
prednisolone, cyclosporine monotherapy, or cyclosporine 
monotherapy followed by a switch to azathioprine and 
prednisolone after 3 months. Nevertheless, a dose-
dependent effect of cyclosporine on cancer development 
was demonstrated in a study using cyclosporine as 
maintenance immunosuppression [57] On the other 
hand, mTORi have previously demonstrated to inhibit 
rather than promote cancer in experimental models and 
to be associated with reduced incidence of posttransplant 
de novo malignancies in human in previous studies [26, 
27, 58–60]. Recent studies and reviews [61, 62] have 
suggested no association between the drug itself and risk 
of cancer development and all-cause mortality in KT 
recipients. Our results showed an increased risk of cancer 
with cyclosporine vs tacrolimus and MMF treatment 
1 year after-KT. However, this association was lost after 
adjustment for covariates.
All these data suggest that no immunosuppressive 
treatment strategies have been proved to reduce non-
skin PTM risk. This entails an arduous decision for the 
nephrologist when choosing the best immunosuppression 
therapy, especially in those patients with high risk of 
cancer.
Additionally, based on our findings and previous 
literature, developing PTM entails a much lower survival 
rate in KT recipients compared to patients who did not 
develop cancer. Survival after 10 years of follow-up was 
79.1%, lower than those patients without malignancy 
after KT. In fact, not only the survival would be poorer 
compared to recipients without cancer, but also compared 
to those individuals with cancer in general population 
[35, 63]. Farrugia et al.[7] recently described the higher 
malignancy-related mortality rates among KT recipients 
versus general population and stratified by age and gender. 
However, making direct comparisons between transplant 
recipients and general population could lead to inaccurate 
data, as adjustments cannot be fully made for certain types 
of people that are over-represented in a specific cohort. 
Similar findings have been described in other studies: in 
a Dutch kidney transplant cohort, malignancies in KT 
population were more aggressive and developed at a much 
later stage than those in patients without transplants. This 
led to a lower median patient survival after the diagnosis 
of cancer (2.7 years compared to an average survival of 
recipients without cancer of 8.3 years [p <0.0001]) [64]. 
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Eventually, ANZDATA registry and other studies [10, 65] 
have underlined that one-third of deaths with a functioning 
allograft is due to cancer.
KT recipients who develop cancer represent a 
challenge since they require a more complex therapeutic 
approach. On one hand, immunosuppressive treatment 
tends to be minimized due to the diagnosis of malignancy 
albeit the possibility of rejection. And secondly, these 
patients may receive less aggressive cancer treatment due 
to comorbidities. All these elements contribute to worse 
prognosis for many malignancies in immunosuppressed 
hosts.
Cancer is a major limitation in achieving optimal 
outcomes in organ transplantation. Its incidence is high 
and it entails poorer prognoses. Further development of 
approaches to prevention and screening early detection of 
malignancy may play an important role in reducing the 
burden of malignancies in KT recipients. Thus, prevention 
of post-transplant malignancy-related morbidity and 
mortality must be considered a main endpoint in solid 
organ transplant programs [38, 39, 66–68]. Clinical 
guidelines recommend routine cancer screening for all 
KT patients, but these recommendations are mostly 
extrapolated from the general population [69, 70]. In fact, 
there is sparse evidence to support routine screening, risk 
factors management, and interventional therapies for KT 
patients [71–73].
The strengths of our study included the high 
validity of the cancer diagnoses based on cytological 
and pathological evidence, and the long duration of the 
follow-up that allowed us to detect the late-onset cancers, 
increasing the statistical power. Regarding limitations, 
this was a retrospective study and some relevant clinical 
information might be limited. Second, the comparison 
with the general population was taken from data reported 
in the literature (Catalan Registry of Cancer), which may 
constitute a selection bias. However, both the area and the 
time span of the reference population were similar to those 
in our cohort. Moreover, the number of patients in our 
cohort is not large enough to accurate the estimated risks 
of less common cancers. Finally, risk factors of cancers 
such as lifestyle, smoking and alcohol use, ultraviolet 
exposure, skin type, family history or oncogenic viruses 
such as HPV or EBV were not recorded in the database.
In summary, the increased incidence of cancer in 
KT when compared with the general population occurs 
mostly in women. Lung is the most common solid 
organ affected, accounting for 30% of all solid organ 
cancers in our cohort. Bladder, gynecological and lung 
cancers had the greatest SIRs compared to the general 
population. More importantly, thymoglobulin could be 
a modifiable risk factor. Our findings should stimulate 
research into carcinogenic mechanisms associated with 
organ transplantation. A greater understanding of cancer-
related incidence and/or mortality risk after KT will 
allow clinicians to tailor modifiable risk factors such as 
immunosuppression. Antitumor surveillance in selected 
patient groups, particularly in women, and further 
development of prevention and screening strategies are 
needed to improve transplant outcomes.
MATERIALS AND METHODS
Patients
This retrospective cohort study used clinical and 
epidemiological information collected among 1038 
individuals who, between 1979 and 2014, underwent 
KT in Hospital del Mar, Barcelona, Spain. Patients with 
a follow-up shorter than 90 days after KT (n = 96) and 
those who were lost to follow-up (n = 17) were excluded 
from the analysis. The final cohort consisted of 925 KT. 
Median time to follow-up was 8 (interquartile range (IQR) 
3.26–11.29) years.
Study variables
Recorded baseline data included recipient 
characteristics (age, sex, ethnicity, body mass index, 
cause of ESKD [categorized as diabetic nephropathy, 
glomerulonephritis, PKD, vascular/hypertensive disease, 
interstitial nephropathy, unknown or other], time on 
dialysis before transplant, type of RRT [categorized 
as pre-dialysis, hemodialysis, peritoneal dialysis or 
KT]), comorbidities (diabetes, coronary artery disease, 
peripheral vascular disease, cerebrovascular disease, 
previous cancer, human immunodeficiency virus, hepatitis 
B virus, hepatitis C virus), and transplant related factors 
such as the era of transplantation.
All patients with a clinical diagnosis of cancer after 
KT (solid organ tumors and lymphomas) were considered 
as cases. A cancer diagnosis required documentation of 
histopathological evidence. Skin tumors were excluded for 
the analysis.
Statistical analysis
Continuous data were expressed as means ± 
standard deviation (SD) or median and IQR according 
to their distribution. Categorical data were expressed as 
percentages. Comparisons of baseline characteristics 
between recipients with and without cancer were made 
using Chi2 or Fisher's exact tests to analyze categorical 
variables, Student's T-test for continuous variables 
with normal distribution, and Mann–Whitney test for 
nonparametric variables.
Risk factors for cancer diagnosis were evaluated 
through Poisson Regression model. Cox proportional 
hazards models were used to assess death-censored graft 
loss, uncensored graft loss and all-cause mortality. Death-
censored graft loss was considered from the transplant 
date to the beginning of an alternative RRT (return to 
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dialysis o re-transplantation). For non-censored for death 
graft survival (uncensored graft loss) time of exposure was 
considered from the transplant date to the beginning of an 
alternative RRT or death.
Survival analysis of cancer patients and non-cancer 
patients was performed using Kaplan–Meier survival 
curves, applying the log-rank test.
Relative risks of non-skin cancers compared to 
the general population in Catalonia were expressed as 
SIRs, and these were computed using sex- and organ 
location. Confidence intervals were calculated using 
Vandenbroucke short-cut method. Cancer incidence in 
Catalonia was collected from the existing literature [32, 
74, 75].
Statistical analysis was performed using STATA 15.0 
version. A p value <0.05 was considered as statistically 
significant.
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